Huntington's Disease (HD) Center Without Walls-Overview The theme of this long-standing and very successful HD Center is investigation of the HD pathogenic process, beginning at its starting point, the genetic defect and proceeding to its inevitable clinical and neuropathological consequences. As in the past, HD Center investigators continue to approach the problem interactively, creating a synergistic energy that has fostered great advances. In past cycles, we mapped the HD defect, identified it as a CAG repeat expansion, discovered huntingtin aggregates as a new pathologic correlate, developed genotype-phenotype correlations to guide further investigations, and created accurate genetic mouse models of HD. In this renewal cycle, we place a major focus on defining factors that modify HD pathogenesis, as these represent valid targets for the development of rational therapeutics badly needed in HD. Project 1 (Gusella): Genetic and Chemical Modifiers in HD will use molecular genetic analysis to identify modifiers of HD initiation and pathogenesis and characterize their modes of action. Project 2 (Myers): Genetic Studies of Huntington's Disease will perform statistical genetic and bioinformatics analyses to complement molecular efforts in Projects 1 and 3 in defining genetic modifiers of HD onset, progression and disease manifestations. Project 3 (MacDonald): Modifiers of Steps in HD Pathogenesis will test huntingtin interacting proteins as potential HD modifiers and will utilize the accurate genetic knock-in mouse model of HD to define genetic modifiers of pathogenesis. These projects will be supported by cores for Administration (Gusella), Small Molecule Screening (Stein), and Genotyping (MacDonald). Collectively, our studies represent a concerted effort to understand HD and promise to continue the achievements of this HD Center. They also have a realistic potential to benefit HD patients, as targets and compounds will be investigated in a true drug development paradigm (LEAD optimization, animal testing, human trials;outside the scope of this grant) by the non-profit High Q Foundation, which has made a major organizational and financial commitment to capitalize on basic science findings from academic studies such as those of this long-standing HD Center.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS016367-30
Application #
7883259
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Sutherland, Margaret L
Project Start
1997-07-01
Project End
2012-03-31
Budget Start
2010-04-01
Budget End
2012-03-31
Support Year
30
Fiscal Year
2010
Total Cost
$1,396,364
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Lee, Jong-Min; Chao, Michael J; Harold, Denise et al. (2017) A modifier of Huntington's disease onset at the MLH1 locus. Hum Mol Genet 26:3859-3867
HD iPSC Consortium (2017) Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice. Nat Neurosci 20:648-660
Chao, Michael J; Gillis, Tammy; Atwal, Ranjit S et al. (2017) Haplotype-based stratification of Huntington's disease. Eur J Hum Genet 25:1202-1209
Shin, Aram; Shin, Baehyun; Shin, Jun Wan et al. (2017) Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels. Hum Mol Genet 26:1258-1267
Keum, Jae Whan; Shin, Aram; Gillis, Tammy et al. (2016) The HTT CAG-Expansion Mutation Determines Age at Death but Not Disease Duration in Huntington Disease. Am J Hum Genet 98:287-98
Correia, Kevin; Harold, Denise; Kim, Kyung-Hee et al. (2015) The Genetic Modifiers of Motor OnsetAge (GeM MOA) Website: Genome-wide Association Analysis for Genetic Modifiers of Huntington's Disease. J Huntingtons Dis 4:279-84
Lee, Jong-Min; Kim, Kyung-Hee; Shin, Aram et al. (2015) Sequence-Level Analysis of the Major European Huntington Disease Haplotype. Am J Hum Genet 97:435-44
Ramos, Eliana Marisa; Gillis, Tammy; Mysore, Jayalakshmi S et al. (2015) Haplotype analysis of the 4p16.3 region in Portuguese families with Huntington's disease. Am J Med Genet B Neuropsychiatr Genet 168B:135-43
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium (2015) Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease. Cell 162:516-26
Biagioli, Marta; Ferrari, Francesco; Mendenhall, Eric M et al. (2015) Htt CAG repeat expansion confers pleiotropic gains of mutant huntingtin function in chromatin regulation. Hum Mol Genet 24:2442-57

Showing the most recent 10 out of 42 publications